Hancock Jaffe steps closer to launching Colombian VenoValve trial
Hancock Jaffe Laboratories (NSDQ:HJLI) said today it won approval from Colombia’s Medical Research Committee at Fundación Santa Fe de Bogotá to launch a first-in-human trial of its VenoValve bioprosthetic valve. The Irvine, Calif.-based company’s VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis. The company said that with the approval, it will begin to gather data necessary to submit an application to Colombia’s FDA equivalent, the Insti...
Source: Mass Device - August 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular hancockjaffelabs Source Type: news

Cleveland Clinic researchers receive $4.7 million NIH grant to prevent cancer-associated thrombosis
(Cleveland Clinic) The National Heart, Lung and Blood Institute, part of the National Institutes of Health, awarded a $4.7 million grant to Cleveland Clinic to study the prevention of life-threatening, cancer-associated blood clots. The new funding will support a Cleveland Clinic-led research consortium, which will focus on developing strategies to prevent cancer-associated thrombosis (blood clot formation), a potential side effect of cancer treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 8, 2018 Category: Cancer & Oncology Source Type: news

' Good' Cholesterol May Not Be So in Postmenopausal Women
TUESDAY, Aug. 7, 2018 -- Elevated high-density lipoprotein cholesterol (HDL-C) may not always be cardioprotective in postmenopausal women, according to a study published online July 19 in Arteriosclerosis, Thrombosis, and Vascular Biology. Samar R.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 7, 2018 Category: Pharmaceuticals Source Type: news

Cardiovascular Risks Elevated in Transgender Women
(MedPage Today) -- Estrogen use tied to over fivefold increase in venous thromboembolism risk (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 6, 2018 Category: American Health Source Type: news

NextGen Medical targets clots in large vessels
NexGen Medical Systems announced the successful completion of the first human use of its XCOIL  large vessel (18mm) thrombectomy system for the treatment of deep vein thrombosis (DVT). The new device represents an expansion of the company’s 12mm XCOIL system and is designed to rapidly remove blood clots in large vessels, such as the iliac vein. Both XCOIL systems are comprised of an encapsulator sheath and a retractor catheter. The retractor is used to engage and extract the clot, pull it into the encapsulator and remove the clot from the body while minimizing the need for clot-dissolving lytic dr...
Source: Mass Device - August 6, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Cardiovascular nextgenmedical Source Type: news

LSU health research discovers new link between hypoxia and blood clot risk
(Louisiana State University Health Sciences Center) Research led by Rinku Majumder, PhD, Associate Professor of Biochemistry at LSU Health New Orleans School of Medicine, has found how hypoxia (a low concentration of oxygen) decreases Protein S, a natural anticoagulant, resulting in an increased risk for the development of potentially life-threatening blood clots (thrombosis). Although hypoxia has been associated with an increased risk for thrombosis, this research showed for the first time a molecular cause. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news

Antidepressants, Depression Tied to Increased Thromboembolism Risk Antidepressants, Depression Tied to Increased Thromboembolism Risk
The first meta-analysis of its kind shows that antidepressants and depression are both associated with an increased risk for venous thromboembolism. However, the results should be interpreted with caution.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

VTE Prophylaxis After Gastrectomy May Boost Bleeding in Asian Patients VTE Prophylaxis After Gastrectomy May Boost Bleeding in Asian Patients
In Asian patients, symptomatic venous thromboembolism (VTE) after gastrectomy is extremely rare, and pharmacological prophylactic measures may prompt bleeding complications, Korean researchers say.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 27, 2018 Category: Radiology Tags: General Surgery News Source Type: news

Hancock Jaffe wins OK from ethics committee for FIH VenoValve trial
Hancock Jaffe Laboratories (NSDQ:HJLI) said today that Colombia’s Ethics Committee at Fundación Santa Fe de Bogotá approved a first-in-human trial of its VenoValve bioprosthetic valve. The Irvine, Calif.-based company’s VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis. Hancock Jaffe said that it is also waiting for approval from the FSFB’s medical research committee to launch the trial, according to a press release. Last month, the under...
Source: Mass Device - July 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Regulatory/Compliance Vascular hancockjaffelabs Source Type: news

Depression and antidepressants are associated with an increased risk of venous thromboembolism
In the first review of its kind, new research has found that depression and the use of antidepressants are each associated with an increased risk of venous thromboembolism (VTE). The study led by academics from the Musculoskeletal Research Unit at the University of Bristol has also shown that each of the various classes of antidepressant medications are associated with an increased risk of VTE. (Source: University of Bristol news)
Source: University of Bristol news - July 24, 2018 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences; Press Release Source Type: news

Depression and antidepressants are associated with an increased risk of VTE
(University of Bristol) In the first review of its kind, new research has found that depression and the use of antidepressants are each associated with an increased risk of venous thromboembolism (VTE). The study led by academics from the Musculoskeletal Research Unit at the University of Bristol has also shown that each of the various classes of antidepressant medications are associated with an increased risk of VTE. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 24, 2018 Category: International Medicine & Public Health Source Type: news

DOACs May Cut Cranial Bleed Risk, Up Survival in Women With AF DOACs May Cut Cranial Bleed Risk, Up Survival in Women With AF
Female sex increases the risk for thromboembolism when other risk factors are present, and perhaps in the future, patient sex may be considered to guide AF therapy choices, says one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 19, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Trial Adds Gemcitabine to Pleural Mesothelioma HIOC Therapy
Results of a phase I clinical trial highlight how the addition of a drug to an existing treatment option appears safe and may improve outcomes in certain patients with malignant pleural mesothelioma (MPM). The primary goal of the trial was to determine the maximum tolerated dose of gemcitabine added to cisplatin when these drugs are delivered together as heated intraoperative chemotherapy (HIOC) during surgery. Researchers have studied cisplatin alone for HIOC. The addition of gemcitabine — a chemotherapy drug often used to treat pancreatic, ovarian and breast cancers — is new. The Journal of Thoracic Oncology...
Source: Asbestos and Mesothelioma News - July 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Increased Mortality With Vena Cava Filters Stirs Controversy Increased Mortality With Vena Cava Filters Stirs Controversy
The use of vena cava filters in patients with venous thromboembolism and a contraindication to anticoagulation is associated with an increase in 30-day mortality, results of a new observational show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

How fast can acute stroke treatment become to still be reliable?
(University of Helsinki) Neurologists around the world are aware that the delivery of thrombolytic treatment for stroke in Helsinki University Hospital, Finland, is freaking fast -- but is it too fast? A new study published on July 11 in the journal Neurology clarified whether the team of neurologists in Helsinki actually have enough time to diagnose stroke correctly before it is treated. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2018 Category: International Medicine & Public Health Source Type: news

Transgender Women at High Risk of Thromboembolism, Stroke Transgender Women at High Risk of Thromboembolism, Stroke
Cross-sex estrogen taken by transgender women appears to increase the risk of thromboembolism in a way that seems very different from that observed when postmenopausal women take HRT.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

AngioDynamics takes a hit after missing Q4 numbers
AngioDynamics (NSDQ:ANGO) failed to meet expectations for its fiscal fourth quarter, sending share prices sharply down today despite a swing to black ink. Latham, N.Y.-based AngioDynamics posted profits of $2.1 million, or 6¢ per share, on sales of $88.3 million for the three months ended May 31. That compares with losses of -$12.9 million during fiscal Q4 2017 and amounts to top-line growth of 1.6%. Adjusted to exclude one-time items, earnings per share were 20¢, a penny below the consensus forecast on Wall Street, where analysts were looking for sales of $89.3 million. Full-year profits surged 226.2% to $1...
Source: Mass Device - July 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat AngioDynamics Source Type: news

Transfeminine Persons Have Increased VTE Incidence
TUESDAY, July 10, 2018 -- Transfeminine individuals have increased rates of venous thromboembolism (VTE) compared with cisgender men and cisgender women, with more pronounced differences for those initiating hormone therapy, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 10, 2018 Category: Pharmaceuticals Source Type: news

ASH to collaborate on clinical practice guidelines on von Willebrand Disease
(American Society of Hematology) The American Society of Hematology (ASH) will collaborate with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), World Federation of Hemophilia (WFH), and the University of Kansas Medical Center to develop clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD).   (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2018 Category: International Medicine & Public Health Source Type: news

Early TAVR Leaflet Thrombosis Not Harmful, Study Says (CME/CE)
(MedPage Today) -- Single-center series, with anticoagulant Tx for most, leaves open questions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 20, 2018 Category: Cardiology Source Type: news

DVT symptoms: Four signs of deep vein thrombosis to watch for when you fly this summer
DVT, which stands for deep vein thrombosis, is when a blood clot develops within a deep vein in the body, usually in the leg. The condition has long being associated with flying and the complications can be fatal. So what symptoms and signs should you watch out for when you fly away on your holiday this summer? (Source: Daily Express - Health)
Source: Daily Express - Health - June 19, 2018 Category: Consumer Health News Source Type: news

Are YOU at risk of developing a shock blood clot from flying?
Travel-related deep vein thrombosis (DVT) has remained a hot topic ever since the link with long-haul flights was first recognized in the last 10 years. Dr Sarah Brewer lays out the risk factors. (Source: the Mail online | Health)
Source: the Mail online | Health - June 18, 2018 Category: Consumer Health News Source Type: news

Over-allotment takes Hancock Jaffe IPO to nearly $9m
The underwriter of an initial public offering by Hancock Jaffe Laboratories (NSDQ:HJLI) this week exercised in full its over-allotment option, taking the gross proceeds from the flotation to nearly $9 million. The IPO, which priced on the last day of May, initially brought in $7.5 million for Irvine, Calif.-based Hancock Jaffe, which makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass grafts. The shares trade on the NASDAQ exchange under the symbol “HJLI.” Network 1 Financial Securities, the offering’s managi...
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Vascular Wall Street Beat hancockjaffelabs Source Type: news

VTE Linked to Acute Decline in Physical Function in Women
FRIDAY, June 15, 2018 -- For women, venous thromboembolism (VTE) is associated with acute decline in physical function, according to a study published online June 8 in the Journal of Thrombosis and Haemostasis. Kaitlin A. Hagan, Sc.D., from Brigham... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 15, 2018 Category: Pharmaceuticals Source Type: news

E-Cigarette Flavorings May Impair Vascular Function
THURSDAY, June 14, 2018 -- Flavoring additives used in electronic cigarettes (e-cigarettes) may have adverse effects on blood vessels, according to a study published online June 14 in Arteriosclerosis, Thrombosis, and Vascular Biology. Jessica L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2018 Category: Pharmaceuticals Source Type: news

Post-Op VTE Risk Up After Intra-Op Blood Transfusion
(MedPage Today) -- Deep vein thrombosis, pulmonary embolism more common within 30 days (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 14, 2018 Category: Cardiology Source Type: news

Peri-Op RBC Transfusions Linked to Postoperative VTE
THURSDAY, June 14, 2018 -- Perioperative red blood cell (RBC) transfusions are associated with the development of new or progressive postoperative venous thromboembolism (VTE), according to a study published online June 13 in JAMA Surgery. Ruchika... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2018 Category: Pharmaceuticals Source Type: news

APAGBI: Teens 13 & #43; Should Be Assessed for VTE Prophylaxis
TUESDAY, June 12, 2018 -- In the perioperative period, post-pubertal adolescents should be assessed for venous thromboembolism (VTE) prophylaxis because of their slightly elevated risk, according to a special article from the Association of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 12, 2018 Category: Pharmaceuticals Source Type: news

Car travel-related thrombosis: fact or fiction? - Lippi G, Favaloro EJ.
The condition sometimes referred to as "economy class syndrome," and also known as "traveler's thrombosis," is a distinctive pathological condition characterized by occurrence of venous thromboembolism (VTE) in a patient who has recently experienced a l... (Source: SafetyLit)
Source: SafetyLit - June 11, 2018 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Life-threatening pulmonary embolism that occurred immediately after acute carbon monoxide poisoning in the emergency department - Lee SJ, Cha YS, Lee Y, Kim H.
We report the first case of a life-threatening PE that occu... (Source: SafetyLit)
Source: SafetyLit - June 11, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Pulmonary thromboembolism after carbon monoxide poisoning: a case series and review of the literature - Lee Y, Lim TH, Kang H, Oh J, Ko BS.
OBJECTIVE: Carbon monoxide (CO) poisoning is known to increase thrombotic tendency, and the risk of deep vein thrombosis in individuals who have experienced CO poisoning is higher than in the general population. However, there are a few reports describing ... (Source: SafetyLit)
Source: SafetyLit - June 11, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Pitt's David Vorp named Fellow of the American Heart Association
(University of Pittsburgh) David A. Vorp, Associate Dean for Research and John A. Swanson Professor of Bioengineering at the University of Pittsburgh Swanson School of Engineering, was named a Fellow of the American Heart Association (FAHA) in recognition of his innovative and sustained contributions in scholarship, education, and volunteer service to the organization. Vorp's election was conferred by the Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) recognizing his work in those fields. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2018 Category: International Medicine & Public Health Source Type: news

Hancock Jaffe prices $8m IPO below the range
Medical device developer Hancock Jaffe Laboratories yesterday priced its initial public offering below the re-set range it issued last week, raising nearly $8 million. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. Last December the company said it planned to float nearly 1.9 million shares at $6 to $8 apiece, for gross proceeds of $11.3 million to $15.0 million, or $13.1 million at the midpoint. But last week Hancock Jaffe cut the amount of shares to roughly 1.1 million...
Source: Mass Device - June 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Wall Street Beat hancockjaffelabs Source Type: news

Reduced-Dose Anticoagulants Feasible for Extended VTE Tx
TUESDAY, May 29, 2018 -- For an extended duration, reduced-dose direct oral anticoagulants (DOACs) may be as effective as full-dose treatment for preventing recurrent venous thromboembolism (VTE), according to a review published online May 17 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 30, 2018 Category: Pharmaceuticals Source Type: news

Abbott ’s Amplatzer Stroke Reduction Data Is Strong at EuroPCR
Abbott Laboratories’ Amplatzer Amulet left atrial appendage (LAA) occlusion device has been shown at one year to reduce stroke by 57% as compared to the predicted stroke risk. The data also showed it was able to make this reduction without the need for lifetime blood thinners.  The Abbott Park IL-based company released the data at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions in Paris, and simultaneously published in EuroIntervention. More than 1,078 patients suffering from atrial fibrillation (Afib) were in the study with one-year-follow up. “The Amul...
Source: MDDI - May 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Hancock Jaffe re-sets the range for $8m IPO
Medical device developer Hancock Jaffe Laboratories yesterday re-set the range on a pending initial public offering, which would fetch roughly $8 million at the midpoint. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. Last December the company said it planned to float nearly 1.9 million shares at $6 to $8 apiece, for gross proceeds of $11.3 million to $15.0 million, or $13.1 million at the midpoint. In a new filing yesterday, Hancock Jaffe cut the amount of shares to roughly 1.1 m...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Vascular Wall Street Beat hancockjaffelabs Source Type: news

Extended INR Test Intervals Safe for Warfarin-Treated Patients
WEDNESDAY, May 23, 2018 -- For stable warfarin-treated patients, extended international normalized ratio (INR) testing can be successfully and safely implemented, according to a study published online May 15 in the Journal of Thrombosis and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 23, 2018 Category: Pharmaceuticals Source Type: news

Inari Medical wins FDA 510(k) for FlowTriever
Inari Medical said today it won FDA 510(k) clearance for its FlowTriever stent retriever designed to treat pulmonary embolisms. The clearance came based upon results from the company’s Flare clinical study of the device, which examined data from 106 patients with acute pulmonary embolisms treated with the FlowTriever at 18 US sites, the Irvine, Calif.-based company said. Results from the study indicated a decrease in mean RV/LV ratio from baseline of 1.53 to 1.15 at 48 hours post-procedure. Data also indicated excellent safety at 30 days with a 3.8% rate of major adverse events and no device related complication...
Source: Mass Device - May 22, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Regulatory/Compliance Vascular Inari Medical Source Type: news

Rivaroxaban Linked to Low VTE Recurrence in Active Cancer
MONDAY, May 21, 2018 -- For patients with active cancer and venous thromboembolism (VTE), rivaroxaban is associated with lower VTE recurrence compared with dalteparin, but with elevated clinically relevant non-major bleeding (CRNMB), according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2018 Category: Pharmaceuticals Source Type: news

What is BACM?
Discussion Leg pain in children has a broad differential diagnosis and includes more innocuous problems such as growing pains and transient synovitis but also more serious problems including neurological diseases or malignancy. Occult or self-limited trauma are also common causes. A review can be found here. Limping can be painful or painless and has its own differential diagnosis which can overlap with leg pain. A differential diagnosis for limping can be found here. Muscle weakness also has its’ own differential diagnosis which can be found here. Learning Point Benign acute childhood myositis (BACM) has other names...
Source: PediatricEducation.org - May 21, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

May 18, 2018 This Week in Cardiology May 18, 2018 This Week in Cardiology
Device-related thrombosis with Watchman left atrial appendage closure, debulking atrial fibrillation after ablation, rivaroxaban for stroke prevention, alteplase, and Lp(a) are discussed this week.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2018 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

SurModics acquires Embolitech thrombectomy tech for $5m
SurModics (NSDQ:SRDX) said today it inked a deal with Embolitech to acquire its thrombectomy platform the and associated intellectual property in a deal worth $5 million up front, with additional payments based on regulatory milestones. The newly acquired tech platform is designed for use in the peripheral vasculature to remove hard blood clots, Eden Prairie, Minn.-based SurModics said. SurModics added that it plans to leverage its design, development and manufacturing capabilities to advance the platform into different peripheral and vascular applications. “We are pleased to sign an agreement with Surmodic...
Source: Mass Device - May 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Mergers & Acquisitions Vascular SurModics Inc. Source Type: news

Strokes From Clot on Watchman LAA Closure Device: OAC Insights Strokes From Clot on Watchman LAA Closure Device: OAC Insights
The risks for ischemic and hemorrhagic stroke climbed whenever thrombus was seen on the implanted left atrial appendage occluder, often after oral anticoagulants were halted, in a pooled analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 14, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

HRS 2018: Device-related blood clots with Boston Scientific ’ s Watchman implant
Data from a study of device-related blood clots and the Watchman cardiac implant made by Boston Scientific (NYSE:BSX), presented today at the annual meeting of the Heart Rhythm Society in Boston, indicate the need for aggressive management of patients at risk for device-related thrombosis. There were 74 incidences of DRT in 65 of the 1,739 Watchman patients examined in the study, or 3.7%; eight of those patients had multiple DRTs and two experienced embolic events (0.45%). There was no significant difference in mortality between patients with DRT and those without, according to the study. Lead author Dr. Vivek Reddy, ...
Source: Mass Device - May 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Boston Scientific HRS 2018 Source Type: news

HRS 2018 Roundup: Device-related blood clots with Boston Scientific ’ s Watchman implant
Data from a study of device-related blood clots and the Watchman cardiac implant made by Boston Scientific (NYSE:BSX), presented today at the annual meeting of the Heart Rhythm Society in Boston, indicate the need for aggressive management of patients at risk for device-related thrombosis. There were 74 incidences of DRT in 65 of the 1,739 Watchman patients examined in the study, or 3.7%; eight of those patients had multiple DRTs and two experienced embolic events (0.45%). There was no significant difference in mortality between patients with DRT and those without, according to the study. Lead author Dr. Vivek Reddy, ...
Source: Mass Device - May 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Apple Bardy Diagnostics Boston Scientific Fitbit HRS 2018 Impulse Dynamics Imricor Medical Systems Inc. medicalgorithmics Medtronic Preventice samsung Source Type: news

Investors win class certification in lawsuit against Abbott ’ s Thoratec
A group of Thoratec shareholders this week won a class certification in a revived suit claiming that Thoratec, now owned by Abbott (NYSE:ABT), and some of its officers hid facts about its HeartMate II heart pump’s rate of thrombosis that would have negatively affected share prices, thereby misleading investors. Investor Bradley Cooper originally brought the suit against the company in January 2014, on behalf of anyone who bought stock between April 29, 2010, and Nov. 27, 2013. Plaintiffs in the case argued that the company failed to warn investors about a blood clot problem with its HeartMate II i...
Source: Mass Device - May 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Legal News Abbott Thoratec Corp. Source Type: news

Perioperative VTE in Urologic Oncology Procedures Perioperative VTE in Urologic Oncology Procedures
Learn more about the risk for venous thromboembolism among patients undergoing major urologic oncology operations, and find out how best to prevent this complication.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2018 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Doctors Beware: Abbott & #039;s HeartMate 3 Has a Safety Problem
Just when it seemed the HeartMate 3 was gaining momentum, Abbott warned physicians that outflow graft twisting may occur after the left ventricular assist device (LVAD) is implanted. The problem can trigger a persistent low-flow alarm that may signal a potential safety risk to patients, such as blood flow or clotting. The Abbott Park, IL-based company has not recalled any of the devices from patients or hospitals, but there have been 32 reports of outflow graft twisting (an incidence rate of 0.72%), including reports of low blood flow, clotting, and three patient deaths. No devices are being recalled from patients or ...
Source: MDDI - May 7, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Implants Source Type: news

Inari Medical touts FlowTriever pulmonary embolism study data
Inari Medical today presented results from a study of its FlowTriever retrieval and aspiration system designed to treat pulmonary embolism, touting the safety and efficacy of the system. Results were presented by Dr. Thomas Tu of Louisville, Ky.’s Baptist Health at the Scientific Sessions of the Society for Cardiovascular Angiography and Interventions in San Diego, Irvine, Calif.-based Inari Medical said. “The significant improvement in right heart function shown with the FlowTriever system compares very favorably with outcomes of other techniques used to treat PE. At the same time, the impressive safety profil...
Source: Mass Device - April 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Inari Medical Source Type: news

Tenecteplase: Thrombolytic of Choice in Stroke? Tenecteplase: Thrombolytic of Choice in Stroke?
The EXTEND-IA TNK trial suggesting better outcomes with tenecteplase than alteplase in the treatment of acute ischemic stroke has now been published in the New England Journal of Medicine.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 26, 2018 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news